

Advent France Biotechnology

Geoffroy de Ribains promoted to partner at Advent France Biotechnology



Geoffroy de Ribains has been promoted to partner at Advent France Biotechnology (AFB). Geoffroy started at AFB in 2019 as an operating partner.

As partner, he will be in charge of sourcing new investments, participating in startup creation, contributing to portfolio companies' growth strategy and acting as interim CEO and member of the board when needed. He will also actively participate in AFB's second fundraising.

Geoffroy was previously CEO of Step Pharma, a Paris-based biotech startup that he co-founded and brought from target discovery to preclinical candidate stage. He is also a co-founder of Biomunex Pharmaceuticals. Geoffroy de Ribains brings with him 12 years of venture capital investing experience at Andera Partners and Atlas Venture. He holds an MSc. in molecular biology from the University of Paris, France.

Combining extensive experience as an investor and an entrepreneur, Geoffroy can rely on a broad network of contacts in the industrial, financial, medical and academic communities across the EU and the US. His expertise includes financing, company building and management, strategic and business planning, and product development in the biotech, medtech and diagnostics industries.

In September 2020 Geoffroy de Ribains was appointed CEO of GAMUT Therapeutics, a biotech company created by AFB, pioneering a unique gene-independent approach to treating the later stages of rod-cone dystrophies such as retinitis pigmentosa. In less than a year, Geoffroy and the AFB team have managed to source this breakthrough scientific project from academic research and create a viable startup, acquired in April 2021 by SparingVision, a key French player in ocular gene therapy.

“His recent successful work with GAMUT Therapeutics, acquired by leading firm SparingVision, is the perfect example of Geoffroy’s extensive expertise as a life sciences investor and as an entrepreneur”

Alain Huriez, chairman and co-founder, AFB

Advent France Biotechnology has built a strong team of experts, both entrepreneurs and investors. This strategy enables the early identification of promising therapeutic innovations and to kickstart companies hand-in-hand with scientific founders and academic institutions.

As an early-stage investor, AFB acts as a catalyst for innovations from academic research, to accelerate its startups development through the team's broad managerial experience and its ongoing contacts with leading biotech, pharma companies, and investors.